Investors Retreat as Novo Nordisk Shares Plunge to Four Year Low Following Drug Trial Results
The pharmaceutical landscape shifted dramatically this week as Novo Nordisk, the Danish giant that has dominated the weight-loss sector, saw its market
by 
Josh Weiner
Josh Weiner